PepGen Inc. (PEPG) Research

PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
PEPG
Price
$1.79
Day change
+5.29%
Market cap
$123.8M
P/E ratio
-1.60x
52-week range
1.01-7.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$5.50

Peer companies

  • Alector, Inc. (ALEC)
  • Applied Therapeutics, Inc. (APLT)
  • Corbus Pharmaceuticals Holdings, Inc. (CRBP)
  • Cardiff Oncology, Inc. (CRDF)
  • Cybin Inc. (CYBN)
  • Elicio Therapeutics, Inc. (ELTX)
  • Fate Therapeutics, Inc. (FATE)
  • Molecular Partners AG (MOLN)

Recent insider activity

  • Kasraian Kasra — S-Sale (1233 shares) on 2026-05-21
  • STRECK PAUL — S-Sale (1832 shares) on 2026-03-04
  • STRECK PAUL — S-Sale (47 shares) on 2026-03-04
  • Donnelly Noel — S-Sale (2032 shares) on 2026-03-04
  • Donnelly Noel — S-Sale (52 shares) on 2026-03-04

Open PepGen Inc. (PEPG) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.